Skip to main content
Premium Trial:

Request an Annual Quote

Robert Goggin

Robert Goggin, who was elected to Vermillion's board in 2013 amid shareholder discontent, will be retiring from the board at the end of his current term, the company said in a document filed with the US Securities and Exchange Commission. 

He will not stand for reelection to the board during Vermillion's 2015 annual shareholders' meeting and told the company that his retirement is not the result of any disagreement with Vermillion. 

Googin was elected to the board two years ago as a candidate put forth by a trio of dissident shareholders that included himself in order to influence Vermillion's then-management team.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.